Initial evaluation of PET/CT with 18 F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients.

Abstract

This first-in-man study was carried out to evaluate the safety, whole-body distribution, dose estimation, and lesion accumulation of 18 F-FSU-880, a newly developed probe targeting prostate-specific membrane antigen. Six prostate cancer patients with known metastatic lesions underwent serial whole-body PET/computed tomography (CT) with 18 F-FSU-880. Blood and urine were analyzed before and after PET/CT. Accumulation of 18 F-FSU-880 in organs and metastatic lesions in serial PET images were evaluated by measuring the standardized uptake values. From the biodistribution data, the organ doses and whole-body effective dose were calculated using OLINDA/EXM software was developed by Dr. Michael Stabin of Vanderbilt University, Nashville, Tennessee, USA. 18 F-FSU-880 PET/CT could be carried out without significant adverse effects. High physiological uptake was observed in the salivary/lachrymal glands and kidneys. The effective dose was calculated to be 0.921 × 10-2 mSv/MBq. Known metastatic lesions were clearly visualized with high image contrast that increased with time, except in 1 patient, whose bone metastases were well-controlled and inactive. The PET/CT with 18 F-FSU-880 could be carried out safely and could clearly visualize active metastatic lesions. The present results warrant further clinical studies with a larger number of cases to verify the clinical utility of 18 F-FSU-880 PET/CT in the management of prostate cancer patients.

• Authors: Tsuneo Saga, Yuji Nakamoto, Takayoshi Ishimori, Takahiro Inoue, Yoichi Shimizu, Hiroyuki Kimura, Shusuke Akamatsu, Takayuki Goto, Hiroyuki Watanabe, Kosuke Kitaguchi, Masao Watanabe, Masahiro Ono, Hideo Saji, Osamu Ogawa, Kaori Togashi
• Journal: Cancer science (Cancer Sci) Vol. 110 Issue 2 Pg. 742-750 (Feb 2019) ISSN: 1349-7006 [Electronic] England
• PMID: 30549183 (Publication Type: Journal Article)
• Copyright: © 2018 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Chemical References

• Radiopharmaceuticals
• AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase

Topics

• Aged
• Aged, 80 and over
• AlkB Homolog 3, Alpha-Ketoglutarate-Dependent Dioxygenase (metabolism)
• Humans
• Male
• Middle Aged
• Positron Emission Tomography Computed Tomography (methods)
• Positron-Emission Tomography (methods)
• Prostate (radiation effects)
• Prostatic Neoplasms (metabolism, radiotherapy)
• Radiopharmaceuticals (therapeutic use)
• Tissue Distribution (physiology)
• Tomography, X-Ray Computed (methods)